Hsu, Wei-FanWei-FanHsuChen, Chuen-FeiChuen-FeiChenLai, Hsueh-ChouHsueh-ChouLaiSu, Wen-PangWen-PangSuLin, Chia-HsinChia-HsinLinChuang, Po-HengPo-HengChuangChen, Sheng-HungSheng-HungChenChen, Ching-HsiangChing-HsiangChenWang, Hung-WeiHung-WeiWangGUAN-TARN HUANGPeng, Cheng-YuanCheng-YuanPeng2023-01-102023-01-102018-041478-3223https://scholars.lib.ntu.edu.tw/handle/123456789/627106The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB) patients remains unclear. We investigated the patterns of serum HBsAg kinetics and their association with therapeutic outcomes in genotype B- or C-infected CHB patients receiving long-term NA therapy.enHBsAg loss; chronic hepatitis B; group-based trajectory models; hepatitis B surface antigen; nucleos(t)ide analogue[SDGs]SDG3journal article10.1111/liv.13564288574112-s2.0-85029476579WOS:000428335300009https://scholars.lib.ntu.edu.tw/handle/123456789/401191